HuntingtonBancshares Incorporated announced that the Board of Directors declared and set aside a quarterly cash dividend on the company's 5.70% Series I Non-Cumulative Perpetual Preferred Stock (Nasdaq: HBANM) of $356.25 per share (equivalent to $0.35625 per depositary share) payable March 2, 2026, to shareholders of record on February 15, 2026. https://mma.prnewswire.com/media/2730277/Huntington_Exception_Logo.jpg About HuntingtonHuntington Bancshares Incorporated […]

(NASDAQ:GRAN), Hong Kong, Dec. 12, 2025 (GLOBE NEWSWIRE) — GRANDE GROUP LIMITED (“GRAN” or the “Company”) (Nasdaq: GRAN), a Hong Kong-based financial services provider which principally engages in the provision of corporate finance advisory services and IPO sponsor services through its Hong Kong subsidiary, Grande Capital Limited, today announced its unaudited financial results for the

(NASDAQ:ZVRA), CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company's common stock (the “Inducement Awards”) to

(NasdaqGM:FLY), NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Firefly Aerospace Inc. (“Firefly Aerospace Inc.” or the “Company”) (NASDAQ: FLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Firefly Aerospace Inc. investors who were adversely affected by alleged securities

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order

A first of its kind randomized trial showed higher survival rates and significantly fewer side effects for patients receiving proton therapy for certain head and neck cancers The study, published today inThe Lancet,showed results from the largest of its kind Phase III trial. Led by researchers at the University of Texas MD Anderson Cancer Center,

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 12, 2025 CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 GlobeNewswire December 12, 2025 TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025

Teva Releases Q4 2025 Aide Memoire GlobeNewswire December 12, 2025 TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public